Quantuvis

📑 Fresenius Kabi recently has launched the biosimilar Otulfi in the U.S. as a treatment for patients aged six and older with conditions like Crohn’s disease and ulcerative colitis. This launch marks the first biosimilar product from the partnership between Fresenius and Formycon.  ✅ In today’s market biosimilars require a carefully tailored contracting strategy to secure payer adoption and avoid exclusion from formularies. PBMs often develop formularies that favor originator biologics due to established rebate agreements, making it challenging for biosimilars to obtain preferred placement. ✨ Navigating biosimilar market access comes with its unique challenges - Quantuvis Platform simplifies these processes, providing the tools and insights needed to make informed decisions and optimize contracting strategies. 🤝 Reach out to us if you want to learn more! 

🫀 The cardiovascular drug development landscape is experiencing a remarkable renaissance, signaling a new era in the fight against heart disease.  💻 Major players like Pfizer and Novartis, alongside innovative biotechs such as BridgeBio and Regenxbio, are vying for their share of this evolving market. With projections indicating growth from approximately $150 billion in 2024 to $207 billion by 2033, there's immense potential for advancements in treatment options and improved patient outcomes.  🔝 This market environment becomes highly competitive and dynamic, making it essential to establish accurate pricing, contracting, and access strategies at product launch and in response to new competitors.     ✅ If you're interested in learning how Quantuvis assists its clients in successfully planning and executing their access and contracting strategies—especially in ambitious and rapidly evolving therapeutic areas—please feel free to reach out to us. 

📢 Is Assembia's AXS25 Summit on your calendar this year? 🤝We will be attending and look forward to networking opportunities! ✅Connect with our Market Access Solutions Experts, Corrado Panno and Gregory Lee, to discover how our clients are utilizing digital-first solutions to enhance gross-to-net strategies, improve access, and drive commercial pull-through.

📊 Today's new biosimilars are stepping into dynamic markets, where PBMs have forged strong connections with reference drugs.  ✔️ In 2025, the Big Three PBMs are poised to reshape their national formularies, favoring their private-label biosimilars over Humira and its myriad biosimilar competitors. Consequently, nearly all marketed Humira biosimilars will find themselves excluded from the larger PBMs' formularies for 2025.  📈 To thrive in the biosimilar landscape, embracing effective channel strategies and tailored solutions is essential to ensure widespread access and uptake. This begins with establishing the right payer contracts from the outset. 📢 At Quantuvis, we proudly present a solution crafted for market access teams. By harnessing your existing data assets and invoice data, we unite these resources into a cloud-based technology platform that empowers in-house analytics and paves the way for success. 

📢 As the year begins, analysts and biotech executives are emphasizing a notable shift in cell therapy from oncology to autoimmune diseases. Additionally, there is a growing interest in next-generation obesity drugs and an increased focus on neuromuscular, kidney, and cardiovascular diseases. ➡️ In this rapidly changing competitive landscape, what tools do you have in place to manage contract deal analytics?  ✅ Our closed-loop deal analytics solutions assist life science companies in unlocking the full potential of their teams. Quantuvis can help you identify market trends, understand contract opportunities, and align strategies accordingly. 

👩⚕️ Health plans are increasingly modifying their benefit designs by transferring specialty drug coverage from the medical benefit to the pharmacy benefit, with coverage criteria differing 14% of the time according to a recent study. 📝 As a result, plans often create separate coverage policies for the same drug. This discrepancy can complicate patients' access to necessary care, as well as forces pharmaceutical companies to face challenges in ensuring rebate accuracy. ✅ By integrating pharmacy and medical benefit data along with contract modeling, Quantuvis helps clients understand these discrepancies in coverage and ensure the right contract strategies and rebates are applied. 

➡️ A recent survey conducted by the Deloitte US Center for Health Solutions reveals that despite several potential disruptive forces poised to transform the life sciences industry by 2025.    📝 Digital transformation continues to be a major priority within the life sciences sector, propelled by advancements in cloud computing, generative AI, and various other digital technologies.    ✔️ At Quantuvis, we provide our clients with AI-powered predictive decision-making capabilities that utilize extensive enterprise payer spines to them to easily ingest and interpret variant and complex datasets that reflect market actuality.    As a result, our clients can achieve continuously adaptive forecasting, pattern-recognizing behavior models, and customizable assumptions that empowers them to move from descriptive analytics to prescriptive modeling. 

📌 Blue Shield of California is taking a groundbreaking approach to address the high cost of drugs by bypassing traditional pharmacy benefit managers and working directly with drug manufacturers. 📉 Through this partnership, the insurer aims to significantly reduce the cost of AbbVie's Humira, the world's top-selling drug, by up to 90%. This initiative, known as Pharmacy Care Reimagined, involves a collaboration with drug manufacturer Fresenius Kabi and Evio Pharmacy Solutions to provide members with better access to more affordable biosimilar medications while eliminating excessive markups often associated with traditional PBM models. 📊 Quantuvis can empower your organization with the ability to fine-tune and test your contract positions effortlessly, ensuring they secure the most advantageous terms during negotiations which streamlines the negotiation process and enhances the ability to achieve favorable outcomes across Payers, PBM’s,  and Trade partners.   

📈 Global AI Adoption Index report, about 42% of large businesses are currently using AI.  Despite the widespread use of AI in various industries, pharmaceutical marketers are proceeding cautiously when it comes to implementing this technology. At a recent event in Philadelphia, marketing leaders from Bayer, Daiichi Sankyo, and argenx discussed the slow integration of AI in pharma marketing and the numerous opportunities it presents for the industry.    📌 How about integrating AI and technology in other aspects of your business? As market headwinds – such as regulatory pressure, PBM consolidation challenge the traditional experience driving operating models, and the data universe becomes more complex, it becomes crucial to integrate technological evolution into the decision-making process.      🔧 What tools do you have available to effectively navigate and mitigate market headwinds?   

🎥 Watch Bill Roth, General Manager and Managing Partner at Blue Fin Group discussing the key takeaways of this year's keynote speech at Access insights.      📉 The pharmaceutical industry is facing significant challenges related to product access and commercialization. Factors like pharmacy economics, prior authorizations, and step edits complicate the launch of new brands, while the rise of generic medications further exacerbates these issues.    To address these challenges, manufacturers are adopting strategies such as collaboration with stakeholders, leveraging data and technology, and innovative product launches.    📊 Given the market headwinds how do you ensure success in planning and executing your access and contract strategy, especially in addressing your budgetary needs for 2025? 📌 Reach out to Quantuvis if you want to learn more about how we have successfully supported our life science customers in streamlining their pricing and contract processes.